<DOC>
	<DOCNO>NCT01706146</DOCNO>
	<brief_summary>Atrial fibrillation ( AF ) common sustain abnormal rhythm heart , affect estimate 2.5 5 million individual US , lead stroke , heart failure , premature death . For AF stroke risk factor , chronic anticoagulation recommend prevent intracardiac thrombus formation stroke even AF infrequent short-lived . This standard care base partly inability rapidly recognize respond AF recurrence often brief asymptomatic , expose patient risk anticoagulant-induced hemorrhage even prolong period sinus rhythm risk stroke presumably low . Recent advance device technology drug therapy , however , potential change way investigator manage AF . The use small leadless subcutaneous implantable cardiac monitor remote data transmission capability ( Reveal XT , Medtronic Inc. ) provide ability remotely continuously evaluate patient AF recurrence , even episodes brief asymptomatic . In addition , release unique oral thrombin inhibitor approve use non-valvular AF ( Dabigatran [ Pradaxa ] , Rivaroxaban [ Xarelto ] ) allow rapid onset anticoagulation within minute hour single oral dose . Together , advance allow continuous AF monitoring target anticoagulation around time AF episode , thereby reduce risk drug-induced hemorrhage still protect stroke . The aim pilot study assess feasibility intermittent anticoagulation rapid-onset oral thrombin inhibitor guide continuous AF-sensing implantable cardiac monitor ( Reveal XT ) remote data transmission capability .</brief_summary>
	<brief_title>Rhythm Evaluation AntiCoagulaTion With COntinuous Monitoring</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Patients must meet following criterion : 1 . Age 18 . 2 . Patients nonvalvular , noncontinuous AF either : ( A ) Infrequent AF episodes without rhythm control strategy document AF last &gt; 1 hour 3 consecutive month ( last 2 previously implant Reveal XT implantable cardiac monitor ) , ( B ) Previous current rhythm control strategy . Rhythm control strategy may include : . Class I Class III antiarrhythmic drug ii . Pulmonary vein isolation iii . PostMAZE/minimally invasive MAZE 3 . Current Reveal XT implant prior study enrollment . 4 . Documented clinical history symptomatic asymptomatic paroxysmal , longstanding persistent persistent AF prior rhythm control initiation . The duration AF must &gt; 30 second documented external monitor , present 12 lead ECG , Reveal XT . 5 . CHADS2 score 1 2 6 . Candidates chronic anticoagulation FDAapproved nonCoumadin oral anticoagulant ( dabigatran , rivaroxaban , apixaban ) , base discretion treat physician . 7 . Demonstrated ability tolerate dabigatran 150mg/BID ( CrCl &gt; 30ml/min ) , rivaroxaban 15mg QD ( CrCl 1549 ml/min ) 20mg QD ( CrCl ≥50ml/min ) , apixaban 5mg BID 2.5 mg subject ≥2 follow : age ≥ 80 year , body weight ≤60kg , serum creatinine ≥1.5 mg/dl . 8 . Able willing provide write informed consent willing follow instruction , attend require study visit , undergo plan test . 9 . Subject must willing able discontinue oral anticoagulation purpose study Patients follow criterion : 1 . Permanent AF 2 . Any documented single AF episode last ≥ 1 hour per month two consecutive month prior study enrollment . Mechanical prosthetic valve severe valve disease . 3 . CHADS2 score 0 , &gt; 2 4 . Subject deem high risk noncardioembolic stroke ( i.e . significant carotid artery disease ) base discretion investigator . 5 . Individual pregnant , nursing , plan become pregnant . 6 . Known hypersensitivity nonCoumadin oral anticoagulant . 7 . Documented prior stroke transient ischemic attack . 8 . Reversible cause AF ( e.g. , cardiac surgery , pulmonary embolism , untreated hyperthyroidism ) . 9 . Conditions associate increase risk bleeding : Major surgery previous month Planned surgery intervention next 3 month . History intracranial , intraocular , spinal , retroperitoneal atraumatic intraarticular bleed Gastrointestinal hemorrhage within past year unless cause permanently eliminate ( e.g . surgery ) Symptomatic endoscopically document gastroduodenal ulcer disease previous 30 day Hemorrhagic disorder bleed diathesis Need anticoagulant treatment disorder AF Required use nonaspirin antiplatelet agent ( i.e. , Plavix ) time enrollment Uncontrolled hypertension ( SBP &gt; 180 mmHg and/or DBP &gt; 100 mmHg ) 10 . Recent malignancy radiation therapy ( ≤6 month ) 11 . Anemia ( hemoglobin &lt; 10g/dL ) thrombocytopenia ( platelet count &lt; 100K/UL ) 12 . Patients receive investigational drug past 30 day participate drug study . 13 . Intolerance hypersensitivity low dose aspirin therapy 14 . Life expectancy less expected duration trial due concomitant disease . 15 . Any concomitant condition , opinion investigator , would allow safe participation study ( e.g. , drug addiction , alcohol abuse ) . 16 . Inability comply daily data transmission requirement . 17 . Known history isolate atrial flutter/atrial tachycardia without atrial fibrillation . 18 . More 10 false positive atrial fibrillation event last &gt; 30 minute per month two month prior enrollment previously implantable cardiac monitor . 19 . Severe renal impairment ( CrCl &lt; 15 ml/min )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>atrial fibrillation</keyword>
	<keyword>reveal xt</keyword>
	<keyword>oral anticoagulation</keyword>
	<keyword>dabigatran</keyword>
	<keyword>rivaroxaban</keyword>
	<keyword>apixaban</keyword>
</DOC>